Akash Maniam: The optimal management of upper tract urothelial carcinoma is far from clear

Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post by International Urology Cancer Summit on LinkedIn, adding:

“Great question. The optimal management of upper tract urothelial carcinoma is far from clear. Higher fibroblast growth factor receptors (FGFR) alteration rates, lower immunotherapy response rates, differences in tumour mutational burden/microenvironment etc.

How do you or would you treat this at your centre? Chemotherapy alone, chemotherapy and IO, enfortumab-vedotin/Pembrolizumab

Would you enrol into a clinical trial example targeting Fibroblast growth factor receptor (FGFR) 1st line? Vote and comment, would be an enriching discussion!”

 Quoting International Urology Cancer Summit’s post: